MCID: BLD131
MIFTS: 59

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bladder Urothelial Carcinoma

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 11 14
Transitional Cell Carcinoma of the Bladder 28 5
Transitional Cell Carcinoma of Bladder 11 71
Bladder Transitional Cell Carcinoma 11 16
Tcc - [transitional Cell Carcinoma] of Bladder 33
Urinary Bladder Urothelial Carcinoma 11
Carcinoma Transitional Cell Bladder 53
Urothelial Bladder Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4006
NCIt 49 C39851
SNOMED-CT 68 393562002
ICD11 33 1237451411
UMLS 71 C0279680

Summaries for Bladder Urothelial Carcinoma

Disease Ontology: 11 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary: Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to bladder cancer and papilloma. An important gene associated with Bladder Urothelial Carcinoma is TUG1 (Taurine Up-Regulated 1), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Bifidobacterium and Acidophilus have been mentioned in the context of this disorder. Affiliated tissues include lining of the bladder, lymph node and prostate, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 554)
# Related Disease Score Top Affiliating Genes
1 bladder cancer 31.2 TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
2 papilloma 31.1 TP53 KRAS FGFR3 ERBB2 CDKN2A AKT1
3 vulva cancer 30.9 TP53 PIK3CA ERBB2 CDKN2A
4 schimmelpenning-feuerstein-mims syndrome 30.9 PIK3CA KRAS FGFR3
5 vulval paget's disease 30.9 ERBB2 CDKN2A
6 penile cancer 30.9 TP53 PIK3CA CDKN2A
7 adenoma 30.8 TP53 PIK3CA KRAS CTNNB1 CDKN2A AKT1
8 villous adenoma 30.8 TP53 KRAS CTNNB1
9 nevus, epidermal 30.8 PIK3CA KRAS FGFR3 AKT1
10 exanthem 30.7 KRAS ERBB2 AKT1
11 brain cancer 30.7 U2AF1 TP53 PIK3CA CTNNB1 AKT1
12 adenocarcinoma 30.7 TP53 PIK3CA MALAT1 KRAS FGFR3 ERBB2
13 ureteral benign neoplasm 30.7 TP53 FGFR3
14 plasmacytoma 30.6 PVT1 GAS5 CDKN2A AKT1
15 carcinosarcoma 30.6 TP53 PIK3CA KRAS FBXW7 ERBB2 CTNNB1
16 suppression of tumorigenicity 12 30.6 U2AF1 TP53 PIK3CA ERBB2 CTNNB1 CDKN2A
17 thyroid carcinoma 30.6 PVT1 MALAT1 HOTAIR GAS5
18 human papillomavirus infectious disease 30.6 TP53 PIK3CA ERBB2 CDKN2A AKT1
19 basal cell nevus syndrome 30.6 TP53 CTNNB1 AKT1
20 thyroid cancer, nonmedullary, 1 30.6 TP53 PVT1 MEG3 MALAT1 HOTAIR
21 rectal benign neoplasm 30.6 TP53 PIK3CA KRAS CTNNB1
22 signet ring cell adenocarcinoma 30.6 TP53 KRAS ERBB2 CTNNB1
23 li-fraumeni syndrome 30.6 U2AF1 TP53 PIK3CA KRAS ERBB2 CTNNB1
24 cervical squamous cell carcinoma 30.5 TP53 PIK3CA KRAS FBXW7 EP300 CDKN2A
25 large cell carcinoma 30.5 TP53 KRAS ERBB2
26 diffuse gastric cancer 30.5 TP53 PIK3CA KRAS ERBB2 CTNNB1
27 lynch syndrome 30.5 U2AF1 TP53 PIK3CA KRAS FBXW7 ERBB2
28 sarcoma 30.5 TP53 PIK3CA KRAS HOTAIR CTNNB1
29 colon adenocarcinoma 30.5 TP53 PIK3CA KRAS FBXW7 CTNNB1
30 low grade glioma 30.4 TP53 CDKN2A AKT1
31 mucinous adenocarcinoma 30.4 U2AF1 TP53 PIK3CA KRAS ERBB2 CTNNB1
32 peripheral nervous system disease 30.4 U2AF1 TP53 KRAS ERBB2 CTNNB1 CDKN2A
33 colorectal adenocarcinoma 30.4 TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
34 renal cell carcinoma, papillary, 1 30.3 U2AF1 TP53 PIK3CA KRAS FGFR3 FBXW7
35 gastric adenocarcinoma 30.3 TP53 PIK3CA KRAS HOTAIR FBXW7 ERBB2
36 cholangiocarcinoma 30.3 TUG1 TP53 PIK3CA MALAT1 KRAS ERBB2
37 adrenal cortical carcinoma 30.3 TP53 PIK3CA KRAS ERBB2 CTNNB1 CDKN2A
38 head and neck cancer 30.3 U2AF1 TP53 PIK3CA KRAS GAS5 ERBB2
39 retinoblastoma 30.3 TP53 MEG3 MALAT1 HOTAIR EP300 CDKN2A
40 endocervical adenocarcinoma 30.3 U2AF1 TP53 PIK3CA FBXW7 ERBB2 EP300
41 colonic benign neoplasm 30.3 TP53 PIK3CA KRAS FBXW7 ERBB2 CTNNB1
42 melanoma 30.3 TP53 PVT1 PIK3CA MEG3 MALAT1 KRAS
43 small cell cancer of the lung 30.3 TUG1 TP53 PIK3CA MALAT1 HOTAIR CDKN2A
44 pancreatic adenocarcinoma 30.2 U2AF1 TP53 RXRA PIK3CA KRAS ERBB2
45 suppressor of tumorigenicity 3 30.2 TP53 CDKN2A
46 squamous cell carcinoma 29.9 TUG1 TP53 PIK3CA MALAT1 KRAS HOTAIR
47 breast cancer 29.9 TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
48 prostate cancer 29.8 TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
49 pancreatic cancer 29.7 TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
50 renal cell carcinoma, nonpapillary 29.6 U2AF1 TUG1 TP53 PVT1 PIK3CA MEG3

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

25 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.68 KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.68 KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.68 KRAS
4 Decreased viability GR00106-A-0 10.68 KRAS
5 Decreased viability GR00221-A-1 10.68 AKT1 FGFR3 KRAS PIK3CA CDKN2A RXRA
6 Decreased viability GR00221-A-2 10.68 AKT1 EP300 FGFR3 KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.68 AKT1 FGFR3 CDKN2A
8 Decreased viability GR00221-A-4 10.68 AKT1 PIK3CA CDKN2A
9 Decreased viability GR00249-S 10.68 AKT1 FGFR3 RXRA
10 Decreased viability GR00301-A 10.68 KRAS
11 Decreased viability GR00381-A-1 10.68 KRAS RXRA
12 Decreased viability GR00402-S-2 10.68 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.77 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.77 FBXW7
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.77 FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.77 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.77 AKT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.77 KRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.77 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.77 FBXW7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.77 AKT1 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.77 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.77 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 AKT1
25 Increased cell migration GR00055-A-1 9.16 CTNNB1
26 Increased cell migration GR00055-A-3 9.16 CTNNB1
27 Increased CDKN1A mRNA expression GR00389-S-1 8.32 EP300

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.41 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
2 homeostasis/metabolism MP:0005376 10.41 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
3 nervous system MP:0003631 10.39 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
4 normal MP:0002873 10.37 AKT1 CREBBP CTNNB1 EP300 ERBB2 FBXW7
5 cellular MP:0005384 10.33 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
6 muscle MP:0005369 10.31 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
7 embryo MP:0005380 10.29 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
8 endocrine/exocrine gland MP:0005379 10.26 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
9 no phenotypic analysis MP:0003012 10.24 CDKN2A CTNNB1 FGFR3 HOTAIR KRAS MALAT1
10 digestive/alimentary MP:0005381 10.24 CDKN2A CREBBP CTNNB1 EP300 ERBB2 FBXW7
11 immune system MP:0005387 10.22 AKT1 CDKN2A CREBBP CTNNB1 EP300 FBXW7
12 liver/biliary system MP:0005370 10.21 AKT1 CDKN2A CREBBP CTNNB1 FBXW7 KRAS
13 cardiovascular system MP:0005385 10.21 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
14 limbs/digits/tail MP:0005371 10.15 CREBBP CTNNB1 ERBB2 FGFR3 HOTAIR KRAS
15 respiratory system MP:0005388 10.15 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
16 craniofacial MP:0005382 10.13 CREBBP CTNNB1 EP300 ERBB2 FBXW7 FGFR3
17 skeleton MP:0005390 10.1 AKT1 CDKN2A CREBBP CTNNB1 ERBB2 FGFR3
18 pigmentation MP:0001186 10.08 CDKN2A CTNNB1 KRAS RXRA TP53 U2AF1
19 vision/eye MP:0005391 9.96 CDKN2A CTNNB1 EP300 FBXW7 FGFR3 KRAS
20 hematopoietic system MP:0005397 9.93 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
21 mortality/aging MP:0010768 9.83 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
22 integument MP:0010771 9.4 AKT1 CDKN2A CREBBP CTNNB1 ERBB2 FBXW7

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Bifidobacterium Phase 4
2 Acidophilus Phase 4
3
Aminolevulinic acid Approved Phase 3 106-60-5 137
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Nivolumab Approved Phase 3 946414-94-4
8
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
BCG vaccine Approved, Investigational Phase 3
11
Mitomycin Approved Phase 3 50-07-7 5746
12
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
13
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
14
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
15
Laevulinic Acid Experimental Phase 3 123-76-2 11579
16 Angiogenesis Inhibitors Phase 3
17 Photosensitizing Agents Phase 3
18 Vitamins Phase 3
19 Mitogens Phase 3
20 Endothelial Growth Factors Phase 3
21 Pharmaceutical Solutions Phase 3
22 Immunologic Factors Phase 3
23 Vaccines Phase 3
24 Protein Kinase Inhibitors Phase 3
25 Anti-Bacterial Agents Phase 3
26 Antibiotics, Antitubercular Phase 3
27 Adjuvants, Immunologic Phase 3
28 Fluoroquinolones Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 3
30
Aflibercept Approved Phase 2 862111-32-8 124490314
31
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
32
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
33
Ramucirumab Approved, Investigational Phase 2 947687-13-0
34
Epirubicin Approved Phase 2 56420-45-2 41867
35
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
36
Altretamine Approved Phase 2 645-05-6 2123
37
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
38
Tremelimumab Approved, Investigational Phase 2 745013-59-6
39
Ipilimumab Approved Phase 2 477202-00-9
40
Durvalumab Approved, Investigational Phase 2 1428935-60-7
41
Daunorubicin Approved Phase 2 20830-81-3 30323
42
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
43
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
44
Dimethyl sulfoxide Approved, Vet_approved Phase 1, Phase 2 67-68-5 679
45
Lenograstim Approved, Investigational Phase 2 135968-09-1
46
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
49
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
50
Trastuzumab Approved, Investigational Phase 2 180288-69-1

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma Recruiting NCT05220124 Phase 4 Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
2 A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma Not yet recruiting NCT05488353 Phase 4 Disitamab Vedotin for Injection,Penpulimab Injection
3 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
4 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
5 Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
6 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
7 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
8 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
9 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
10 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Completed NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
11 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
12 Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE) Recruiting NCT04637594 Phase 3 Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab
13 MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer Recruiting NCT05092958 Phase 3 Avelumab;Cabozantinib S-malate
14 Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
15 Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial Recruiting NCT04574960 Phase 3 Gemcitabine;Cisplatin;Carboplatin
16 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Active, not recruiting NCT03091660 Phase 3
17 Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation Active, not recruiting NCT03244384 Phase 3
18 A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients. Not yet recruiting NCT05037279 Phase 3 Bacillus Calmette-Guerin: Strain Russian BCG-I;Bacillus Calmette-Guerin: Strain TICE
19 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
20 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
21 A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00352079 Phase 3 gefitinib
22 The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
23 A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS) Unknown status NCT02662309 Phase 2 MPDL3280A
24 A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
25 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
26 A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma Unknown status NCT03113266 Phase 2
27 A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
28 A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
29 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Completed NCT03081858 Phase 1, Phase 2 TSD-001
30 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
31 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
32 Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
33 A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) Completed NCT00112671 Phase 2 sorafenib tosylate
34 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
35 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
36 Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2
37 Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression Completed NCT01828736 Phase 2 Gemcitabine;Carboplatin;Cisplatin
38 A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract Completed NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
39 Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00526656 Phase 2 sunitinib malate
40 Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00136175 Phase 2 Paclitaxel;Carboplatin;Gemcitabine
41 Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder Completed NCT00963859 Phase 2
42 An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy Completed NCT01282463 Phase 2 Docetaxel
43 Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. Completed NCT01620970 Phase 2 PF03446962
44 Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management Completed NCT00343356 Phase 2 Trement
45 A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder Completed NCT00047216 Phase 2 tipifarnib
46 Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT01599013 Phase 2 Vinflunine, Gemcitabine;Vinflunine, Carboplatin
47 Acupuncture vs. Standard of Care for Induction Intravesical BCG-Related Adverse Events in High-Risk Non-Muscle Invasive Bladder Cancer Completed NCT04496219 Phase 2
48 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
49 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
50 A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer Completed NCT00238420 Phase 1, Phase 2 Paclitaxel

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 28

Anatomical Context for Bladder Urothelial Carcinoma

Organs/tissues related to Bladder Urothelial Carcinoma:

FMA: Lining Of The Bladder
MalaCards : Lymph Node, Prostate, Lung, Endothelial, Liver, Myeloid, Kidney

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 3890)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 5
24625776 2014
3
Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. 53 62
19332900 2009
4
Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. 53 62
19178674 2008
5
E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. 53 62
18931551 2008
6
Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). 53 62
18210748 2007
7
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. 53 62
17311310 2007
8
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 53 62
17311305 2007
9
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. 53 62
17222615 2007
10
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 53 62
17293658 2007
11
Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. 53 62
17034609 2006
12
[Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof]. 53 62
17064593 2006
13
p53 protein in serum and urine samples of patients with bladder transitional cell carcinoma and its overexpression in tumoral tissue. 53 62
17559044 2006
14
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. 53 62
16040097 2005
15
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. 53 62
15733109 2005
16
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. 53 62
15117815 2004
17
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. 53 62
14981105 2004
18
p53 Gene mutations in superficial bladder cancer. 53 62
15539839 2004
19
[Expression of cyclooxygenase in bladder transitional cell carcinoma]. 53 62
14981815 2004
20
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. 53 62
12731328 2003
21
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. 53 62
11839665 2002
22
The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. 53 62
14577491 2002
23
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 53 62
11696726 2001
24
Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. 53 62
11528193 2001
25
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. 53 62
11342899 2001
26
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication. 53 62
11523249 2001
27
[The study on relation of human papillomavirus and P53 expression with bladder transitional cell carcinoma]. 53 62
11471022 2000
28
The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. 53 62
10687971 2000
29
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. 53 62
10699635 2000
30
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. 53 62
12840920 2000
31
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 53 62
10658909 2000
32
A novel tumor-specific gene therapy for bladder cancer. 53 62
10532707 1999
33
[Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma]. 53 62
10466059 1999
34
Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? 53 62
9817302 1998
35
The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. 53 62
9891547 1998
36
Expression of bcl-2 and bcl-X in bladder cancer. 53 62
9507882 1998
37
Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. 53 62
9111623 1997
38
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. 53 62
9187909 1997
39
Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. 53 62
8871928 1996
40
[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. 53 62
9275651 1996
41
[Ectopic production of HCG beta by bladder carcinoma in vitro and in vivo]. 53 62
8709440 1996
42
Expression of p53 product in Chinese human bladder carcinoma. 53 62
7688167 1993
43
MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. 62
36441170 2023
44
Incidental findings on staging CT for rectal cancer: Frequency, clinical significance and outcomes. 62
36356382 2023
45
Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer. 62
36054443 2023
46
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. 62
36190522 2022
47
Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. 62
36320325 2022
48
["Surgery only" is not enough: potential of multimodal therapy in urothelial bladder carcinoma]. 62
36352266 2022
49
Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study. 62
35787739 2022
50
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. 62
36451132 2022

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

5 (show top 50) (show all 276)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RXRA NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe) SNV Likely Pathogenic
376528 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
2 MAP2K1 NM_002755.4(MAP2K1):c.371C>A (p.Pro124Gln) SNV Likely Pathogenic
40743 rs397516792 GRCh37: 15:66729163-66729163
GRCh38: 15:66436825-66436825
3 FBXW7 NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln) SNV Likely Pathogenic
376427 rs759610249 GRCh37: 4:153244184-153244184
GRCh38: 4:152323032-152323032
4 RXRA NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr) SNV Likely Pathogenic
376529 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
5 MTOR NM_004958.4(MTOR):c.7255G>A (p.Glu2419Lys) SNV Likely Pathogenic
156709 rs587777900 GRCh37: 1:11174420-11174420
GRCh38: 1:11114363-11114363
6 PIK3CA NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg) SNV Likely Pathogenic
376480 rs1057519931 GRCh37: 3:178916929-178916929
GRCh38: 3:179199141-179199141
7 MTOR NM_004958.4(MTOR):c.6040G>A (p.Glu2014Lys) SNV Likely Pathogenic
376131 rs1057519780 GRCh37: 1:11187857-11187857
GRCh38: 1:11127800-11127800
8 RHEB NM_005614.4(RHEB):c.103T>A (p.Tyr35Asn) SNV Likely Pathogenic
376515 rs1057519949 GRCh37: 7:151188050-151188050
GRCh38: 7:151490964-151490964
9 RHEB NM_005614.4(RHEB):c.104A>G (p.Tyr35Cys) SNV Likely Pathogenic
376516 rs1057519950 GRCh37: 7:151188049-151188049
GRCh38: 7:151490963-151490963
10 SF3B1 NM_012433.4(SF3B1):c.1874G>A (p.Arg625His) SNV Likely Pathogenic
376534 rs1057519961 GRCh37: 2:198267483-198267483
GRCh38: 2:197402759-197402759
11 SF3B1 NM_012433.4(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely Pathogenic
376535 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
12 PIK3CA NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val) SNV Likely Pathogenic
376479 rs1057519930 GRCh37: 3:178916930-178916930
GRCh38: 3:179199142-179199142
13 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely Pathogenic
376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
14 U2AF1 NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely Pathogenic
376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
15 ERBB2 NM_004448.4(ERBB2):c.2305G>T (p.Asp769Tyr) SNV Likely Pathogenic
375992 rs121913468 GRCh37: 17:37880261-37880261
GRCh38: 17:39724008-39724008
16 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
17 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely Pathogenic
376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
18 ERBB2 NM_004448.4(ERBB2):c.2033G>A (p.Arg678Gln) SNV Likely Pathogenic
376344 rs1057519862 GRCh37: 17:37879658-37879658
GRCh38: 17:39723405-39723405
19 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely Pathogenic
376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
20 NFE2L2 NM_006164.5(NFE2L2):c.235G>C (p.Glu79Gln) SNV Likely Pathogenic
376465 rs1057519922 GRCh37: 2:178098810-178098810
GRCh38: 2:177234082-177234082
21 ERBB3 NM_001982.4(ERBB3):c.310G>T (p.Val104Leu) SNV Likely Pathogenic
376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
22 CNOT9 NM_005444.3(CNOT9):c.259T>C (p.Ser87Pro) SNV Likely Pathogenic
376526 rs1057519956 GRCh37: 2:219447748-219447748
GRCh38: 2:218583025-218583025
23 NFE2L2 NM_006164.5(NFE2L2):c.86A>G (p.Asp29Gly) SNV Likely Pathogenic
376464 rs1057519921 GRCh37: 2:178098959-178098959
GRCh38: 2:177234231-177234231
24 HRAS, LRRC56 NM_005343.4(HRAS):c.183G>T (p.Gln61His) SNV Likely Pathogenic
376318 rs121913496 GRCh37: 11:533873-533873
GRCh38: 11:533873-533873
25 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely Pathogenic
376419 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
26 ERBB2 NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe) SNV Likely Pathogenic
376189 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
27 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Likely Pathogenic
17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
28 FBXW7 NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His) SNV Likely Pathogenic
376425 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
29 U2AF1 NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr) SNV Likely Pathogenic
376026 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
30 NFE2L2 NM_006164.5(NFE2L2):c.85G>A (p.Asp29Asn) SNV Likely Pathogenic
376463 rs1057519920 GRCh37: 2:178098960-178098960
GRCh38: 2:177234232-177234232
31 ERBB3 NM_001982.4(ERBB3):c.889G>T (p.Asp297Tyr) SNV Likely Pathogenic
376407 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
32 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
33 NFE2L2 NM_006164.5(NFE2L2):c.85G>T (p.Asp29Tyr) SNV Likely Pathogenic
376462 rs1057519920 GRCh37: 2:178098960-178098960
GRCh38: 2:177234232-177234232
34 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely Pathogenic
376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
35 NFE2L2 NM_006164.5(NFE2L2):c.237G>T (p.Glu79Asp) SNV Likely Pathogenic
376468 rs1057519924 GRCh37: 2:178098808-178098808
GRCh38: 2:177234080-177234080
36 CNOT9 NM_005444.3(CNOT9):c.260C>G (p.Ser87Cys) SNV Likely Pathogenic
376527 rs1057519957 GRCh37: 2:219447749-219447749
GRCh38: 2:218583026-218583026
37 ERBB2 NM_004448.4(ERBB2):c.2263_2264delinsCC (p.Leu755Pro) INDEL Likely Pathogenic
13877 rs121913469 GRCh37: 17:37880219-37880220
GRCh38: 17:39723966-39723967
38 MAP2K1 NM_002755.4(MAP2K1):c.370C>T (p.Pro124Ser) SNV Likely Pathogenic
375981 rs1057519732 GRCh37: 15:66729162-66729162
GRCh38: 15:66436824-66436824
39 NFE2L2 NM_006164.5(NFE2L2):c.85G>C (p.Asp29His) SNV Likely Pathogenic
376461 rs1057519920 GRCh37: 2:178098960-178098960
GRCh38: 2:177234232-177234232
40 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely Pathogenic
69961 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
41 ERBB3 NM_001982.4(ERBB3):c.890A>T (p.Asp297Val) SNV Likely Pathogenic
376408 rs1057519892 GRCh37: 12:56482342-56482342
GRCh38: 12:56088558-56088558
42 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely Pathogenic
376474 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
43 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>A (p.Gly13Ser) SNV Likely Pathogenic
376323 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
44 SF3B1 NM_012433.4(SF3B1):c.1873C>G (p.Arg625Gly) SNV Likely Pathogenic
376536 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
45 CDKN2A NM_000077.5(CDKN2A):c.247C>G (p.His83Asp) SNV Likely Pathogenic
376380 rs121913385 GRCh37: 9:21971111-21971111
GRCh38: 9:21971112-21971112
46 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg) SNV Likely Pathogenic
13970 rs121913357 GRCh37: 7:140481403-140481403
GRCh38: 7:140781603-140781603
47 ERBB2 NM_004448.4(ERBB2):c.2264T>C (p.Leu755Ser) SNV Likely Pathogenic
376035 rs121913470 GRCh37: 17:37880220-37880220
GRCh38: 17:39723967-39723967
48 ERBB2 NM_004448.4(ERBB2):c.2305G>A (p.Asp769Asn) SNV Likely Pathogenic
376403 rs121913468 GRCh37: 17:37880261-37880261
GRCh38: 17:39724008-39724008
49 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
50 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 AKT1 CDKN2A CREBBP CTNNB1 EP300 ERBB2
2
Show member pathways
13.86 TP53 KRAS FGFR3 ERBB2 EP300 CTNNB1
3
Show member pathways
13.82 TP53 PIK3CA KRAS FGFR3 FBXW7 ERBB2
4 13.78 TP53 RXRA PIK3CA KRAS FGFR3 FBXW7
5
Show member pathways
13.75 TP53 KRAS FGFR3 ERBB2 EP300 CREBBP
6
Show member pathways
13.68 TP53 RXRA KRAS FGFR3 ERBB2 EP300
7
Show member pathways
13.58 AKT1 CREBBP EP300 ERBB2 FGFR3 KRAS
8
Show member pathways
13.4 TP53 PIK3CA KRAS FGFR3 ERBB2 EP300
9
Show member pathways
13.39 AKT1 CREBBP CTNNB1 EP300 ERBB2 FBXW7
10
Show member pathways
13.1 AKT1 CREBBP EP300 FGFR3 KRAS TP53
11
Show member pathways
13.02 RXRA PIK3CA KRAS EP300 CREBBP AKT1
12
Show member pathways
12.92 KRAS EP300 CTNNB1 CREBBP AKT1
13
Show member pathways
12.9 PIK3CA KRAS EP300 CREBBP AKT1
14
Show member pathways
12.88 TP53 PIK3CA KRAS EP300 CREBBP AKT1
15
Show member pathways
12.87 PIK3CA KRAS FGFR3 ERBB2 EP300 CREBBP
16
Show member pathways
12.84 AKT1 CDKN2A CREBBP EP300 RXRA
17
Show member pathways
12.81 TP53 FBXW7 EP300 CREBBP AKT1
18 12.81 PIK3CA KRAS FGFR3 ERBB2 EP300 CTNNB1
19
Show member pathways
12.8 TP53 KRAS CTNNB1 CREBBP AKT1
20 12.72 TP53 PIK3CA FGFR3 CTNNB1 CDKN2A AKT1
21
Show member pathways
12.7 KRAS EP300 CREBBP CDKN2A AKT1
22
Show member pathways
12.68 TP53 PIK3CA KRAS FGFR3 AKT1
23
Show member pathways
12.61 TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
24
Show member pathways
12.5 TP53 PIK3CA ERBB2 CTNNB1 AKT1
25 12.47 TP53 CTNNB1 CREBBP AKT1
26 12.45 TP53 KRAS FGFR3 AKT1
27
Show member pathways
12.45 PIK3CA KRAS CTNNB1 AKT1
28
Show member pathways
12.44 PIK3CA KRAS FGFR3 AKT1
29
Show member pathways
12.44 TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
30
Show member pathways
12.43 PIK3CA KRAS FGFR3 ERBB2 CTNNB1
31
Show member pathways
12.43 TP53 RXRA PIK3CA KRAS FGFR3 ERBB2
32
Show member pathways
12.36 TP53 PIK3CA EP300 AKT1
33
Show member pathways
12.35 PIK3CA KRAS CTNNB1 AKT1
34
Show member pathways
12.34 TP53 PIK3CA KRAS FGFR3 ERBB2 CTNNB1
35 12.32 PIK3CA ERBB2 CTNNB1 AKT1
36 12.29 PIK3CA KRAS FGFR3 AKT1
37
Show member pathways
12.28 TP53 PIK3CA KRAS FGFR3 ERBB2 CTNNB1
38 12.23 TP53 KRAS CTNNB1 AKT1
39
Show member pathways
12.23 RXRA PIK3CA ERBB2 EP300 CREBBP AKT1
40
Show member pathways
12.21 AKT1 CREBBP KRAS TP53
41 12.2 TP53 PIK3CA KRAS CTNNB1 AKT1
42
Show member pathways
12.19 TP53 PIK3CA CDKN2A AKT1
43
Show member pathways
12.19 AKT1 ERBB2 FGFR3 KRAS PIK3CA TP53
44 12.14 TP53 KRAS EP300 CTNNB1 AKT1
45
Show member pathways
12.12 PIK3CA ERBB2 EP300 CTNNB1 AKT1
46 12.1 PIK3CA EP300 CREBBP AKT1
47
Show member pathways
12.09 PIK3CA KRAS ERBB2 AKT1
48 12.08 TP53 KRAS FGFR3 ERBB2 AKT1
49
Show member pathways
12.07 TP53 PIK3CA ERBB2 AKT1
50
Show member pathways
12.02 PIK3CA KRAS ERBB2 AKT1

GO Terms for Bladder Urothelial Carcinoma

Cellular components related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulator complex GO:0005667 9.32 TP53 RXRA EP300 CTNNB1 CREBBP

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.09 TP53 PIK3CA FBXW7 CTNNB1 AKT1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.88 PIK3CA ERBB2 AKT1
3 rhythmic process GO:0048511 9.8 TP53 FBXW7 EP300 CREBBP
4 N-terminal peptidyl-lysine acetylation GO:0018076 9.56 CREBBP EP300
5 vasculature development GO:0001944 9.55 PIK3CA FBXW7 CTNNB1
6 negative regulation of immature T cell proliferation in thymus GO:0033088 9.54 ERBB2 CDKN2A
7 protein destabilization GO:0031648 9.5 FBXW7 EP300 CREBBP CDKN2A
8 positive regulation of gene expression GO:0010628 9.4 TP53 PVT1 KRAS ERBB2 EP300 CTNNB1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear receptor binding GO:0016922 9.8 RXRA EP300 CTNNB1
2 transcription coregulator binding GO:0001221 9.73 RXRA EP300 CTNNB1
3 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.61 TP53 EP300 CTNNB1 CREBBP CDKN2A
4 disordered domain specific binding GO:0097718 9.55 TP53 CTNNB1 CDKN2A
5 peptide N-acetyltransferase activity GO:0034212 8.92 EP300 CREBBP

Sources for Bladder Urothelial Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....